NCT05350501终止2 期
A Phase 2 Trial of EO2040, a miCrobiaL-derived Peptide therApeUtic Vaccine, in Combination With Nivolumab, for Treatment of Patients With ctDNA-dEfined Minimal Residual Disease of CRC Stage II, III, or IV After Curative Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Enterome
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Response to Treatment at 6 Months
研究概览
简要总结
The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy.
详细描述
The microbiome-derived therapeutic vaccine concept utilized in conjunction with anti-Programmed cell Death protein 1 (PD1) blockade is an innovative option for testing of a rational immunotherapy in colorectal cancer. The concept as such, including the combination with nivolumab, has already been tested in the clinical setting (i.e. in recurrent glioblastoma and adrenal tumors) and shown to be well tolerated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be eligible to receive study treatment, a patient must meet all the criteria below:
- •Provided written informed consent prior to any study-related procedures .
- •Histological confirmation of colorectal cancer.
- •Post R0-resection of stages II, III, or IV CRC and completion of all planned standard of care adjuvant therapies.
- •Presence of minimal residual disease as defined by a positive ctDNA assay after completion of all planned standard of care therapies.
- •Age ≥ 18 years old.
- •Human leukocyte antigen (HLA)-A2 positive.
- •No evidence of radiographic disease
- •Predefined performance status
- •Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours prior to randomization.
- •Considering the embryofetal toxicity of the immune checkpoint inhibitor (ICI) shown in animals' models, recommendations for contraception must be followed.
- •Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.
排除标准
- •Patients who meet any of the following criteria will not be eligible to participate in the study:
- •Patients treated with dexamethasone > 2 mg/day or equivalent .
- •Patients treated with radiotherapy within 12 weeks, and cytotoxic chemotherapy therapy within 28 days (or 5 half lives of the compound(s) administered if longer) before study treatment start.
- •Patients with persistent Grade ≥ 2 toxicities (according to NCI-CTCAE v5.0). Toxicities must be resolved for at least 2 weeks to Grade 1 or less. However, alopecia, neuropathy, and other persisting toxicities not constituting a safety risk based on Investigator's judgment are acceptable.
- •Patients who have received any prior treatment with compounds targeting PD1, PD-L1, Cytotoxic T-lymphocyte-associated Antigen 4 (CTLA-4), or similar compounds where general resistance against therapeutic vaccination approaches might have developed.
- •Patients with defined abnormal laboratory values:
- •Patients with presence of other concomitant active, invasive malignancies .
- •Patients with clinically significant active infection, cardiac disease, significant medical or psychiatric disease/condition that, in the opinion of the Investigator, would interfere with the interpretation of patient safety or study results or that would prohibit the understanding or rendering of informed consent
- •Patients with suspected autoimmune or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g., Guillain-Barré syndrome)..
- •Patients with a history of solid organ transplantation or allogeneic hematopoietic stem cell transplantation.
- •Patients with a history or known presence of tuberculosis.
- •Pregnant and breastfeeding patients.
- •Patients with a history or presence of human immunodeficiency virus (HIV) and/or active hepatitis B virus (HBV)/hepatitis C virus (HCV).
- •Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug.
- •Patients with a history of hypersensitivity to any excipient, or active substance, present in the pharmaceutical forms of applicable study treatments.
- •Patients under treatment with immunostimulatory or immunosuppressive medications, including herbal remedies, or herbal remedies known to potentially interfere with major organ function.
- •Patients who have received treatment with any other investigational agent, or participation in another clinical trial
研究组 & 干预措施
Patients With Minimal Residual Disease of Colorectal Cancer
Experimental
Patients With Circulating Tumor DNA-defined Minimal Residual Disease of Colorectal Cancer Stage II, III, or IV After Completion of Curative Therapy
干预措施: EO2040 (Drug)
结局指标
主要结局
Response to Treatment at 6 Months
时间窗: 6 months
Percentage of patients with ctDNA clearance and no radiographic evidence of recurrence
次要结局
- Treatment-Emergent Adverse Events(7 months)
- NCI-CTCAE Grading(7 months)
- Serious Adverse Events(7 months)
- Response to Therapy at 3 Months(3 months)
- DIsease-free Survival(7 months)
- Overall Survival(7 months)
- Immunogenicity and Cross-reactivity(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated DiarrheaRecurrent Clostridium Difficile InfectionNCT01925417Rebiotix Inc.34
已完成
2 期
APX005M and Doxorubicin in Advanced SarcomaSoft Tissue SarcomaNCT03719430Alexander Z. Wei, MD27
已完成
2 期
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary TuberculosisPulmonary TuberculosisNCT02349841TASK Applied Science46
已完成
1 期
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or MelanomaHead and Neck CancerHead and Neck Squamous Cell CarcinomaCell Cancer, SquamousCarcinoma, Squamous CellMelanomaNCT03336606Providence Health & Services13
招募中
2 期
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal CancerColorectal CancerCRCNCT06728072Virginia Commonwealth University97